Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma

Saif,Muhammad  Wasif; Ledbetter,Leslie; Kaley,Kristin; Garcon,Marie  Carmel; Rodriguez,Teresa; Syrigos,Kostas  N.

doi:10.3892/ol.2014.2238

Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma

Authors:
- Muhammad Wasif Saif
- Leslie Ledbetter
- Kristin Kaley
- Marie Carmel Garcon
- Teresa Rodriguez
- Kostas N. Syrigos
View Affiliations

Affiliations: Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA, University of Alabama at Birmingham, Birmingham, AL 35233, USA, Yale School of Medicine, New Haven, CT 06520, USA, Columbia University Medical Center, New York, NY 10027, USA, Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens 115 27, Greece
Published online on: June 11, 2014 https://doi.org/10.3892/ol.2014.2238
Pages: 1302-1306

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Therapeutic options for locally advanced pancreatic cancer (LAPC) include concurrent chemoradiation, induction chemotherapy followed by chemoradiation or systemic therapy alone. The original Gastro‑Intestinal Study Group and Eastern Cooperative Oncology Group studies defined fluorouracil (5‑FU) with concurrent radiation therapy followed by maintenance 5‑FU until progression, as the standard therapy for this subset of patients. Although this combined therapy has been demonstrated to increase local control and median survival from 8 to 12 months, almost all patients succumb to the disease secondary to either local or distant recurrence. Our earlier studies provided a strong rationale for the use of capecitabine in combination with concurrent radiation followed by maintenance capecitabine therapy. To report our clinical experience, we retrospectively evaluated our patients who were treated with maintenance capecitabine. We reviewed the medical records of patients with LAPC who received treatment with capecitabine and radiation, followed by a 4‑week rest, then capecitabine alone 1,000 mg twice daily (ECOG performance status 2 or age >70 years) or 1,500 mg twice daily for 14 days every 3 weeks until progressive disease. We treated 43 patients between September 2004 and September 2012. The population consisted of 16 females and 25 males, with a median age of 64 years (range, 38‑80 years). Patients received maintenance capecitabine for median duration of 9 months (range, 3‑18 months). The median overall survival (OS) for these patients was 17 months, with two patients still living and receiving therapy. The 6‑month survival rate was 91% (39/43), 1‑year survival rate was 72% (31/43) and 2‑year OS rate was 26% (11/43). Grade 3 or 4 toxicity was observed rarely: Hand‑foot syndrome (HFS) in two patients, diarrhea in one patient and peripheral neuropathy in one patient, and there was no mortality directly related to treatment. Capecitabine maintenance therapy following chemoradiation in LAPC offers an effective, tolerable and convenient alternative to 5‑FU. To the best of our knowledge, this is the largest study of its kind which has determined the safety and efficacy of capecitabine maintenance therapy for patients with LAPC.

View Figures

View References

1	American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: 2013
2	Kim R and Saif MW: Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP. 8:279–288. 2007.
3	Oikonomopoulos GM, Huber KE, Syrigos KN and Saif MW: Locally advanced pancreatic cancer. JOP. 14:126–128. 2013.
4	Ng J, Zhang C, Gidea-Addeo D and Saif MW: Locally advanced pancreatic adenocarcinoma: update and progress. JOP. 13:155–158. 2012.
5	Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 80:751–755. 1988.
6	Gastrointestinal Tumor Study Group. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer. 56:2563–2568. 1985.
7	Moertel CG, Frytak S, Hahn RG, et al; Gastrointestinal Study Group. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 48:1705–1710. 1981.
8	Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF and Moertel CG: Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol. 3:373–378. 1985.
9	Cohen SJ, Dobelbower R Jr, Lipsitz S, et al: A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys. 62:1345–1350. 2005.
10	Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr and Holbrook MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 2:865–867. 1969.
11	Whittington R, Neuberg D, Tester WJ, Benson AB III and Haller DG: Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol. 13:227–232. 1995.
12	Ishii H, Okada S, Tokuuye K, Nose H, et al: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer. 79:1516–1520. 1997.
13	Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:2403–2413. 1997.
14	Blackstock AW, Tepper JE, Niedwiecki D, et al: Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 34:107–116. 2003.
15	Moore AM, Cardenes H, Johnson CS, et al: A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: A hoosier oncology group trial. ASCO Annual Meeting. 22:(Abstract 4105). 2004.
16	Epelbaum R, Rosenblatt E, Nasrallah S, Faraggi D, Gaitini D, Mizrahi S and Kuten A: Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol. 81:138–143. 2002.
17	Haddock MG, Swaminathan R, Foster NR, et al: Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol. 25:2567–2572. 2007.
18	Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 34:1274–1281. 1998.
19	Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y and Ishitsuka H: X-ray irradiation induces thymidine phosphory-lase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 5:2948–2953. 1999.
20	Blanquicett C, Saif MW, Buchsbaum DJ, et al: Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res. 11:8773–8781. 2005.
21	Saif MW, Eloubeidi MA, Russo S, et al: Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol. 23:8679–8687. 2005.
22	Saif MW, Black G, Roy S, et al: Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J. 13:247–256. 2007.
23	Huang H, Jiang Z, Wang T, et al: Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 23:718–723. 2012.
24	Chibaudel B, Maindrault-Goebel F, Lledo G, et al: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 27:5727–5733. 2009.
25	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
26	National Cancer Institute. Common Terminology Criteria for Adverse Events. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed September 13, 2013
27	Saif MW, Hashmi S, Zelterman D, Almhanna K and Kim R: Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 23:139–145. 2008.
28	Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 19:4097–4106. 2001.
29	Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 19:2282–2292. 2001.
30	Saif MW, Shi N and Zelt S: Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol. 15:4415–4422. 2009.
31	Cassidy J, Twelves C and Van Cutsem E; Capecitabine Colorectal Cancer Study Group: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 13:566–575. 2002.
32	Kato H, Ichinose Y, Ohta M, et al; Japan Lung Cancer Research Group on Postsurgical Adjuvent Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 350:1713–1721. 2004.
33	Miyashiro I, Furukawa H and Sasako M; Gastric Cancer Surgical Study Group; Japan Clinical Oncology Group. No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer: Randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil in serosa-positive gastric cancer. Japan Clinical Oncology Group 9206-2. In: ASCO Gastrointestinal Cancers Symposium; abstract 4. 2005
34	Sun JF, Wu RR, Norris C, Noone AM, Amankwa-Sakyi M, Slack R and Marshall JL: Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastrointest Cancer Res. 3:134–140. 2009.
35	Saif MW, Wood TE, McGee PJ and Diasio RB: Peripheral neuropathy associated with capecitabine. Anticancer Drugs. 15:767–771. 2004.
36	Cartwright TH, Cohn A, Varkey JA, et al: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 20:160–164. 2001.